Immunovant Inc. Insider Trading
IMVT
Insiders sold $16.3M and bought nothing on the open market.
9% of the selling was scheduled in advance under 10b5-1 plans. Director Andrew J. Fromkin sold $7.44M on May 28, 75% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2022.
Get an email when IMVT's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11 | Atul Pande Director | Sold10b5-1 plan | 3,000 | $36.00 | 108K | 2.1% | Form 4 |
| Oct 28 | Tiago Girao Chief Financial Officer | SoldNo plan | 6,606 | $28.50 | 188K | 2.7% | Form 4 |
| Oct 21 | Jay S Stout Chief Technology Officer | SoldNo plan | 2,595 | $28.94 | 75K | 1.3% | Form 4 |
| Oct 7 | Jay S Stout Chief Technology Officer | SoldNo plan 2 parts | 3,809 | $32.06 average | 122K | 1.9% | Form 4 |
| Oct 7 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan | 1,327 | $32.06 | 43K | 0.8% | Form 4 |
| Oct 7 | Melanie Gloria Chief Operating Officer | SoldNo plan | 2,241 | $32.06 | 72K | 1.0% | Form 4 |
| Oct 2 | Eric Venker Chief Executive Officer | SoldNo plan | 3,506 | $34.11 | 120K | 1.3% | Form 4 |
| Sep 23 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan | 2,846 | $36.36 | 103K | 1.6% | Form 4 |
| Aug 28 | Atul Pande Director | Sold10b5-1 plan | 1,500 | $43.27 | 65K | 1.1% | Form 4 |
| Aug 20 | Melanie Gloria Chief Operating Officer | SoldNo plan | 3,056 | $44.16 | 135K | 1.4% | Form 4 |
| Jul 24 | Atul Pande Director | Sold10b5-1 plan | 1,500 | $39.80 | 60K | 1.1% | Form 4 |
| Jul 23 | Jay S Stout Chief Technology Officer | SoldNo plan | 2,857 | $38.69 | 111K | 1.4% | Form 4 |
| Jul 23 | Tiago Girao Chief Financial Officer | SoldNo plan | 6,798 | $38.69 | 263K | 2.7% | Form 4 |
| Jul 8 | Melanie Gloria Chief Operating Officer | SoldNo plan 2 parts | 2,036 | $39.55 average | 81K | 0.9% | Form 4 |
| Jul 8 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan 2 parts | 1,206 | $39.55 average | 48K | 0.7% | Form 4 |
| Jul 8 | Jay S Stout Chief Technology Officer | SoldNo plan 4 parts | 3,487 | $39.55 average | 138K | 1.6% | Form 4 |
| Jul 2 | Eric Venker Chief Executive Officer | SoldNo plan | 3,092 | $38.48 | 119K | 1.2% | Form 4 |
| Jun 26 | Melanie Gloria Chief Operating Officer | SoldNo plan 2 parts | 17,714 | $38.31 average | 679K | 7.3% | Form 4 |
| Jun 26 | Jay S Stout Chief Technology Officer | SoldNo plan 2 parts | 40,000 | $38.31 average | $1.53M | 16% | Form 4 |
| Jun 26 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan 2 parts | 17,824 | $38.31 average | 683K | 9.0% | Form 4 |
| Jun 26 | Tiago Girao Chief Financial Officer | SoldNo plan | 10,000 | $38.46 | 385K | 3.9% | Form 4 |
| Jun 26 | Atul Pande Director | Sold10b5-1 plan | 1,500 | $38.01 | 57K | 1.1% | Form 4 |
| Jun 18 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan | 2,634 | $35.39 | 93K | 1.4% | Form 4 |
| Jun 15 | Atul Pande Director | Sold10b5-1 plan | 1,500 | $34.02 | 51K | 1.1% | Form 4 |
| May 28 | Andrew J. Fromkin Director | SoldNo plan 2 parts | 221,951 | $33.51 average | $7.44M | 75% | Form 4 |
| May 20 | Melanie Gloria Chief Operating Officer | SoldNo plan 3 parts | 3,115 | $32.45 average | 101K | 1.3% | Form 4 |
| May 20 | Atul Pande Director | Sold10b5-1 plan | 6,000 | $32.00 | 192K | 4.2% | Form 4 |
| May 1 | Robert Graham Susman Director | Sold10b5-1 plan | 2,502 | $27.17 | 68K | 6.4% | Form 4 |
| Apr 23 | Tiago Girao Chief Financial Officer | SoldNo plan | 25,760 | $29.62 | 763K | 9.4% | Form 4 |
| Apr 23 | Jay S Stout Chief Technology Officer | SoldNo plan | 2,754 | $29.62 | 82K | 1.1% | Form 4 |
| Apr 8 | Melanie Gloria Chief Operating Officer | SoldNo plan | 8,722 | $24.83 | 217K | 3.4% | Form 4 |
| Apr 8 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan | 5,165 | $24.83 | 128K | 2.7% | Form 4 |
| Apr 8 | Jay S Stout Chief Technology Officer | SoldNo plan 2 parts | 10,132 | $24.83 average | 252K | 3.8% | Form 4 |
| Apr 2 | Eric Venker Chief Executive Officer | SoldNo plan 2 parts | 14,229 | $24.10 average | 343K | 42% | Form 4 |
| Mar 18 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan | 2,877 | $24.97 | 72K | 1.9% | Form 4 |
| Feb 25 | Melanie Gloria Chief Operating Officer | SoldNo plan 3 parts | 3,238 | $27.85 average | 90K | 1.9% | Form 4 |
| Jan 21 | Jay S Stout Chief Technology Officer | SoldNo plan | 1,977 | $26.03 | 51K | 1.0% | Form 4 |
| Jan 7 | Jay S Stout Chief Technology Officer | SoldNo plan 2 parts | 1,203 | $26.53 average | 32K | 0.6% | Form 4 |
| Dec 18, 2025 | Christopher Van Tuyl Chief Legal Officer | SoldNo plan 2 parts | 10,813 | $26.91 average | 291K | 6.7% | Form 4 |
| Dec 12, 2025 | Roivant Sciences Ltd. Large holder | Bought | 16,666,666 | $21.00 | $350M | 17% | Form 4 |
- Nov 1110b5-1 planAtul PandeDirector · sold 3,000 at $36.00108K2.1% of stake
- Oct 28No planTiago GiraoChief Financial Officer · sold 6,606 at $28.50188K2.7% of stake
- Oct 21No planJay S StoutChief Technology Officer · sold 2,595 at $28.9475K1.3% of stake
- Oct 7No planJay S StoutChief Technology Officer · sold 3,809 at avg $32.06122K1.9% of stake
- Oct 7No planChristopher Van TuylChief Legal Officer · sold 1,327 at $32.0643K0.8% of stake
- Oct 7No planMelanie GloriaChief Operating Officer · sold 2,241 at $32.0672K1.0% of stake
- Oct 2No planEric VenkerChief Executive Officer · sold 3,506 at $34.11120K1.3% of stake
- Sep 23No planChristopher Van TuylChief Legal Officer · sold 2,846 at $36.36103K1.6% of stake
- Aug 2810b5-1 planAtul PandeDirector · sold 1,500 at $43.2765K1.1% of stake
- Aug 20No planMelanie GloriaChief Operating Officer · sold 3,056 at $44.16135K1.4% of stake
- Jul 2410b5-1 planAtul PandeDirector · sold 1,500 at $39.8060K1.1% of stake
- Jul 23No planJay S StoutChief Technology Officer · sold 2,857 at $38.69111K1.4% of stake
- Jul 23No planTiago GiraoChief Financial Officer · sold 6,798 at $38.69263K2.7% of stake
- Jul 8No planMelanie GloriaChief Operating Officer · sold 2,036 at avg $39.5581K0.9% of stake
- Jul 8No planChristopher Van TuylChief Legal Officer · sold 1,206 at avg $39.5548K0.7% of stake
- Jul 8No planJay S StoutChief Technology Officer · sold 3,487 at avg $39.55138K1.6% of stake
- Jul 2No planEric VenkerChief Executive Officer · sold 3,092 at $38.48119K1.2% of stake
- Jun 26No planMelanie GloriaChief Operating Officer · sold 17,714 at avg $38.31679K7.3% of stake
- Jun 26No planJay S StoutChief Technology Officer · sold 40,000 at avg $38.31$1.53M16% of stake
- Jun 26No planChristopher Van TuylChief Legal Officer · sold 17,824 at avg $38.31683K9.0% of stake
- Jun 26No planTiago GiraoChief Financial Officer · sold 10,000 at $38.46385K3.9% of stake
- Jun 2610b5-1 planAtul PandeDirector · sold 1,500 at $38.0157K1.1% of stake
- Jun 18No planChristopher Van TuylChief Legal Officer · sold 2,634 at $35.3993K1.4% of stake
- Jun 1510b5-1 planAtul PandeDirector · sold 1,500 at $34.0251K1.1% of stake
- May 28No planAndrew J. FromkinDirector · sold 221,951 at avg $33.51$7.44M75% of stake
- May 20No planMelanie GloriaChief Operating Officer · sold 3,115 at avg $32.45101K1.3% of stake
- May 2010b5-1 planAtul PandeDirector · sold 6,000 at $32.00192K4.2% of stake
- May 110b5-1 planRobert Graham SusmanDirector · sold 2,502 at $27.1768K6.4% of stake
- Apr 23No planTiago GiraoChief Financial Officer · sold 25,760 at $29.62763K9.4% of stake
- Apr 23No planJay S StoutChief Technology Officer · sold 2,754 at $29.6282K1.1% of stake
- Apr 8No planMelanie GloriaChief Operating Officer · sold 8,722 at $24.83217K3.4% of stake
- Apr 8No planChristopher Van TuylChief Legal Officer · sold 5,165 at $24.83128K2.7% of stake
- Apr 8No planJay S StoutChief Technology Officer · sold 10,132 at avg $24.83252K3.8% of stake
- Apr 2No planEric VenkerChief Executive Officer · sold 14,229 at avg $24.10343K42% of stake
- Mar 18No planChristopher Van TuylChief Legal Officer · sold 2,877 at $24.9772K1.9% of stake
- Feb 25No planMelanie GloriaChief Operating Officer · sold 3,238 at avg $27.8590K1.9% of stake
- Jan 21No planJay S StoutChief Technology Officer · sold 1,977 at $26.0351K1.0% of stake
- Jan 7No planJay S StoutChief Technology Officer · sold 1,203 at avg $26.5332K0.6% of stake
- Dec 18, 2025No planChristopher Van TuylChief Legal Officer · sold 10,813 at avg $26.91291K6.7% of stake
- Dec 12, 2025Roivant Sciences Ltd.Large holder · bought 16,666,666 at $21.00$350M17% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with IMVT
Held by ETFs
IMVT is in 51 US ETFs. The largest of them, with IMVT's weight in each:
Spot a number that looks wrong? Check it in IMVT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMVT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.